Undisclosed SLC15A4 inhibitor
/ OMass Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 15, 2026
OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in…Immunology
(GlobeNewswire)
- "The financing will...support OMass’ earlier-stage pipeline, including generation of initial clinical data for a potential first-in-class SLC15A4 inhibitor for lupus and other diseases associated with interferon overproduction and pathogenic B-cell activation."
Financing • Lupus
1 to 1
Of
1
Go to page
1